The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL).
Youssef Hijazi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen (B)
Matthias Klinger
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andrea Schub
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Min Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Peter Kufer
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andreas Wolf
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Dirk Nagorsen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen